Below is a list of the latest direct early-stage investment deals we are proud to represent
It is our pleasure to introduce you to the venture opportunities we are raising capital for
The vision of cities that evolve around people – not cars
This raiser is the first company to bring blockchain tokenisation to the car sharing market. Their fully electric, free-floating fleet of 200 leased Teslas currently holds 25% market share in Vienna. This flexible and sustainable solution is powered by 100% green energy which makes individual trips greener, but also contributes heavily to the reduction of cars on the road in total. They offer virtual ownership for their users through tokenisation which solves capex shortfalls. Tokens holders receive a profit share when a car is used as well as discounts, promoting brand loyalty as well as non-dilutive capital. Their innovative & proprietary blockchain technology has caught the eye of other vehicle sharing platforms, and they are now opening up their blockchain platform to other mobility companies, alongside expanding the car sharing into Munich this year.
Social Impact end-to-end rental property management platform for all sides
This raiser is a digital solution making property management easier, faster & fairer for social housing associations and independents. Their technology seamlessly connects landlords, tenants & tradespeople with simple, easy to use technology that enhances comm’s and provides any services required. Key IP differentiation of qualification and regulation of the market, driving customer satisfaction & dramatically reducing costs. The UK property management industry is antiquated and with the new 2022 renters reform bill impending, legislating unlimited fines for poor performing landlords. They believe it’s time for the UK’s £30 billion property management industry to adopt new technologies to resolve deep issues with tenant engagement & property knowledge.
Making mental health support accessible and personalised for employees
This raiser’s unique product, is a B2B solution enabling companies to better manage their employee’s mental health in a personalised yet effortless way. They provide mental health first aid training to employees as well as a platform to manage, interact & anonymously capture the data around employee’s mental health. They also provide currency that’s allocated as credits to employees for therapy sessions. The core USP is that individuals have an initial call to assess which therapist would most suit their needs, they can also purchase more if needed and continue with the same therapist, making it far more personalised & effective than current EAP’s. They also make sure the therapy sessions never get wasted, if an employee feels they don’t need them, they can pass them on to family, fellow employees or charity.
Circular Economy for tyres resulting in reusable polymers
This raiser is building a network of local, fully integrated recycling plants that create a circular economy for polymers, with a proof of concept plant operational in the UK. Tyres are a major global waste problem, their solution transforms waste tyres into new resources. An established end to end solution, from waste collection to mechanical processing to chemical recycling. 100% of each tyre will be repurposed into rubber granules, steel, recycled oil or rCB. Site 1 is focused on mechanical processing and revenue generating through tyre collection and rubber granule & steel sales. Site 2 is under development & commercialising by ’24, achieving profitability. The exceptional team has vast expertise chemical engineering and in strategy for securing long term feedstock. They are well placed to have a substantial impact recycling polymers.
These are larger direct ventures that are time sensitive and more dynamic to watch out for
Human Cell Manufacturing
This rev generating bio tech company has a software-like approach to biology, enabling a unique process precisely coding and manufacturing human cells. Their patented technology industrialises and standardises the process of cellular reprogramming, allowing for the first time, highly consistent, large scale batches of human cells to be manufactured. Their technology serves two markets, B2B sales of cells to R&D facilities and cell therapy applications, which are soon to undergo clinical trials.
Here we have an exclusive sneak peak to some of the upcoming raise launches
Reinventing the b2b insurance market